Search results
Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 1 day agoMerck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript April 25, 2024 Merck & Co., Inc. beats...
Cantor Fitzgerald Brokers Boost Earnings Estimates for Merck & Co., Inc. (NYSE:MRK)
ETF DAILY NEWS· 2 days agoMerck & Co., Inc. (NYSE:MRK – Free Report) – Equities research analysts at Cantor Fitzgerald increased their FY2024 earnings per share (EPS) estimates for ...
Merck reports promising V116 vaccine trial results By Investing.com
Investing.com· 2 days agoMerck & Co. (NYSE: MRK) has presented new data from its Phase 3 STRIDE-10 trial of V116, an...
Merck raises 2024 profit forecast on strong cancer, HPV drugs sales
WSAU Wausau· 6 days agoBy Patrick Wingrove (Reuters) - Merck & Co on Thursday raised its annual profit and revenue forecast...
Pfizer’s first-quarter results top estimates, while drugmaker boosts full-year profit outlook
Market Watch· 4 hours agoAn expected drop in COVID-19-related product sales, including antiviral Paxlovid and vaccine...
UPDATE 3-Merck raises 2024 profit forecast on surging sales of cancer drug Keytruda
Reuters via Yahoo Finance· 6 days agoMerck & Co on Thursday raised its annual profit and revenue forecasts on the back of double-digit growth for its blockbuster cancer drug Keytruda, the world's ...
Merck’s first-quarter results beat expectations amid healthy vaccine-sales growth
Market Watch· 6 days agoMerck & Co. Inc. on Thursday reported first-quarter results that beat analysts’ expectations amid...
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Zacks via Yahoo Finance· 6 days agoV116 is Merck’s 21-valent pneumococcal conjugate vaccine, which is under priority review in the...
20 Fastest Growing Health Tech Companies in the World
Insider Monkey via Yahoo Finance· 6 days agoIn this article, we will be taking a look at the 20 fastest growing health tech companies in the...
Merck stock gains on Q1 2024 beat (NYSE:MRK)
Seeking Alpha· 6 days agoMerck (MRK) stock gains as the company posts better than expected Q1 2024 financials with strong sales growth from its cancer medicine Keytruda. Read...